id,title,doi,crossref_paper_link,pdf_url,paper_text,resolver_error,content_type,extracted_info,type
9262389,"Fettner S; Mela C; Wildenhahn F; Tavanti M; Wells C; Mallalieu NL. Evaluation of a tocilizumab autoinjector: results of healthy volunteer bioequivalence and rheumatoid patient human factors studies. Clinical pharmacology and therapeutics. Conference: 119th annual meeting of the american society for clinical pharmacology and therapeutics, ASCPT 2018. United states. (2018) 103 Supplement 1 ppS78-S79",10.1080/17425247.2019.1604678,https://tandfonline.com/doi/pdf/10.1080/17425247.2019.1604678,https://tandfonline.com/doi/pdf/10.1080/17425247.2019.1604678,,,html,,PDF
9736908,NCT00966875. A Study in Patients With Rheumatoid Arthritis. https://clinicaltrials.gov/show/NCT00966875. (2009)   pp,10.1016/b978-032305475-1.50053-7,,,,Missing EZProxy credentials.,unreachable,,na
11086181,Conaghan PG; Ostergaard M; Troum O; Xie Z; Brett A; Snyder M; Ebrahim A; Chapman D; Sawyerr G; Andrews J. Exploring novel tenosynovitis and combined inflammation imaging outcomes: results from a randomised controlled trial in early rheumatoid arthritis. Annals of the rheumatic diseases. (2021) 80 SUPPL 1 pp450-451,10.1136/annrheumdis-2021-eular.364,,,,Missing EZProxy credentials.,unreachable,,na
9261800,Winthrop IV K; Wouters A; Choy EH; Soma K; Hodge J; Nduaka C; Biswas P; McNeil LK; Passador S; Mojcik CF; Rigby WFC. Assessment of immunogenicity of live zoster vaccination (zostavax) in rheumatoid arthritis patients on background methotrexate before and after initiating tofacitinib or placebo. Arthritis and rheumatology. (2015) 67 no pagination pp,10.1136/annrheumdis-2016-eular.1332,,,,Missing EZProxy credentials.,unreachable,,na
9736957,Winthrop K; Wouters A; Choy E; Soma K; Hodge J; Nduaka C; Biswas P; McNeil L; Passador S; Mojcik C; Rigby W. Assessment of immunogenicity of live zoster vaccination in rheumatoid arthritis patients on background methotrexate before and after initiating tofacitinib or placebo. Annals of the rheumatic diseases. (2016) 75 Supplement 2 pp468,10.1136/annrheumdis-2016-eular.1332,,,,Missing EZProxy credentials.,unreachable,,na
11088719,. AORTA - ABATON for RheumaToid Arthritis. . (2021)   pp,10.53347/rid-89980,,,,Missing EZProxy credentials.,unreachable,,na
9738406,EUCTR2018-004539-54-DE. Capability of Tofacitinib or Etanercept to accelerate clinical relevant dose reduction of non-steroidal anti-inflammatory drugs and treat-to-target guided minimization of intake of corticosteroids in patients with active Rheumatoid Arthrtis and an inadequate response to previous csDMARD therapy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-004539-54-DE. (2019)   pp,10.1007/978-3-0348-7720-6_5,http://link.springer.com/content/pdf/10.1007/978-3-0348-7720-6_5.pdf,http://link.springer.com/content/pdf/10.1007/978-3-0348-7720-6_5.pdf,,,pdf,,Page Not Found
9257552,"D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G. Body mass index does not affect response to subcutaneous or intravenous abatacept in patients with rheumatoid arthritis. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp1960-1962",10.1093/rheumatology/kex062.215,http://academic.oup.com/rheumatology/article-pdf/56/suppl_2/kex062.215/19705854/kex062.215.pdf,http://academic.oup.com/rheumatology/article-pdf/56/suppl_2/kex062.215/19705854/kex062.215.pdf,,,pdf,,Article
9261159,Genovese MC; Cobos AC; Leon G; Mysler EF; Keiserman MW; Valente RM; Nash PT; Campos JAS; Porawska W; Box JH; Legerton III CW; Nasonov EL; Durez P; Pappu R; Delaet I; Teng J; Alten R. Subcutaneous abatacept versus intravenous abatacept in patients with rheumatoid arthritis: Long-term data from the acquire trial. Rheumatology (United Kingdom). (2012) 51  ppiii128-iii129,10.1002/art.30463,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.30463,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.30463,,,html,,Page Not Found
9740037,"EUCTR2007-005434-37-AT. A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate. (Short title: mTX-IR Study)  Revised Protocol 02 incorporating Protocol amendment 02 (v2.0 date 19-dec-2007), Protocol amendment 03 (v1.0, date 25-Apr-2008), and Protocol Amendment 06 (v1.0, date 25-Sep-2008). And Anti-TNF failure Substudy Protocol Amendment 05-Site Specific (v2.0, date 02-Oct-2008). - MTX-IR Study. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-005434-37-AT. (2008)   pp",10.3410/f.1097731.553845,,,,Missing EZProxy credentials.,unreachable,,na
9257220,Conaghan PG; Peterfy CG; Di Carlo J; Olech E; Alberts AR; Alper JA; Devenport J; Anisfeld AM; Troum OM. Tocilizumab as monotherapy or in combination with methotrexate associated with early reductions in tissue inflammation: 12 week results from a magnetic resonance imaging substudy of a randomized controlled trial. Rheumatology (United Kingdom). (2012) 51  ppiii24,10.1136/annrheumdis-2013-204762,,,,Missing EZProxy credentials.,unreachable,,na
9260748,Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Annals of the rheumatic diseases. (2013) 72 1 pp43-50,10.1136/annrheumdis-2011-201282,,,,Missing EZProxy credentials.,unreachable,,na
9261013,"Dougados M; Kissel K; Conaghan PG; Mola EM; Schett G; Gerli R; Hansen MS; Amital H; Xavier RM; Troum O; Bernasconi C; Huizinga TW. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the rheumatic diseases. (2014) 73 5 pp803-809",10.1136/annrheumdis-2013-204761,,,,Missing EZProxy credentials.,unreachable,,na
9261164,"Dougados M; Kissel K; Amital H; Conaghan P; Martin-Mola E; Nasonov E; Schett G; Troum O; Veldi T; Bernasconi C; Huizinga T. Double-blind study of tocilizumab+ methotrexate versus tocilizumab+placebo in patients with active rheumatoid arthritis despite prior methotrexate: Progression of structural damage, quality of life and physical function at 24 weeks. Rheumatology (United Kingdom). (2012) 51  ppiii28-iii29",10.1136/annrheumdis-2012-eular.2058,,,,Missing EZProxy credentials.,unreachable,,na
9262463,"Moller B; Scholz G; Dougados M; Huizinga T; Villiger PM; Finckh A. Anemia is a better predictor for radiographic damage in rheumatoid arthritis than DAS28 when determined before start of tocilizumab-treatment-a secondary analysis from the ACT-ray trial. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp569",10.1136/annrheumdis-2017-eular.6685,,,,Missing EZProxy credentials.,unreachable,,na
9742751,"EUCTR2008-001847-20-GR. Randomized placebo-controlled study to evaluate the safety and efficacy of adding tocilizumab (TCZ) to methotrexate (MTX) versus switching to TCZ (placebo controlled), with possible addition of other disease-modifying anti-rheumatic drugs (DMARDs), in patients with active rheumatoid arthritis who have inadequately responded to prior MTX treatment. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-001847-20-GR. (2009)   pp",10.1136/annrheumdis-2014-eular.2178,,,,Missing EZProxy credentials.,unreachable,,na
9740942,NCT00891020. A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs). https://clinicaltrials.gov/show/NCT00891020. (2009)   pp,10.31525/ct1-nct03970837,,,,Missing EZProxy credentials.,unreachable,,na
9737779,"Edwards CJ; Kiely P; Ostor A; Naisbett-Groet B. Tapering MTX versus steady-state MTX in combination with tocilizumab for treatment of rheumatoid arthritis (ACT-TAPER): a randomised, double-blind, controlled phase 4 trial. Annals of the rheumatic diseases. (2016) 75  pp508-",10.1136/annrheumdis-2016-eular.1694,,,,Missing EZProxy credentials.,unreachable,,na
9260526,"Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis and rheumatism. (2008) 58 9 pp2652-2661",10.1002/art.23732,,,,Missing EZProxy credentials.,unreachable,,na
9257189,"Best JH; Pei J. Comparative cost per response for four clinical outcomes of tocilizumab monotherapy versus adalimumab monotherapy in a head-to-head randomized double-blind superiority trial (ADACTA) in patients with rheumatoid arthritis. Value in health. Conference: 23rd annual meeting of the international society for pharmacoeconomics and outcomes research, ISPOR 2018. United states. (2018) 21 Supplement 1 ppS194",10.1016/j.jval.2018.04.1323,,,,Missing EZProxy credentials.,unreachable,,na
9261433,Gabay C; Emery P; Van Vollenhoven R; Dikranian A; Alten R; Klearman M; Musselman D; Agarwal S; Green J; Kavanaugh A. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial. Annals of the Rheumatic Disease. (2013) 71  pp,10.1136/annrheumdis-2012-eular.1963,,,,Missing EZProxy credentials.,unreachable,,na
9262176,Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Annals of the rheumatic diseases. (2016) 75 10 pp1806-1812,10.1136/annrheumdis-2015-207872,,,,Missing EZProxy credentials.,unreachable,,na
9263391,"Gabay C; Emery P; van Vollenhoven R; Dikranian A; Alten R; Pavelka K; Klearman M; Musselman D; Agarwal S; Green J; Kavanaugh A; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England). (2013) 381 9877 pp1541-1550",10.1016/s0140-6736(13)60250-0,,,,Missing EZProxy credentials.,unreachable,,na
9737352,"Gabay C; Emery P; Van Vollenhoven. Erratum: tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (The Lancet (2013) 381 (1541-1550)). Lancet. (2013) 381 9877 pp1540",10.1016/s0140-6736(13)60250-0,,,,Missing EZProxy credentials.,unreachable,,na
9738766,"Best J; Pei J. Comparative cost per response for four clinical outcomes of tocilizumab monotherapy versus adalimumab monotherapy in a head-to-head randomised double-blind superiority trial (ADACTA) in patients with rheumatoid arthritis. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp521",10.1136/annrheumdis-2018-eular.2009,,,,Missing EZProxy credentials.,unreachable,,na
9740251,"EUCTR2009-015845-21-SE. A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009-015845-21-SE. (2010)   pp",10.1016/j.jval.2018.04.1323,,,,Missing EZProxy credentials.,unreachable,,na
9739072,"Gabay C; McInnes I; Kavanaugh A; Tuckwell K; Collinson N; Klearman M; Green J; Sattar N. Changes in lipoprotein(A) after treatment with tocilizumab (TCZ), adalimumab (ADA), and methotrexate (MTX) in patients with Rheumatoid Arthritis (RA). Annals of the rheumatic diseases. (2014) 73 SUPPL. 2 pp",10.1136/annrheumdis-2014-eular.3030,,,,Missing EZProxy credentials.,unreachable,,na
9741194,EUCTR2019-001554-25-NL. Adalimumab dose optimization in rheumatoid arthritis using drug                 concentration in blood (ADDORA): multi-center open label randomized                 controlled trail. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2019-001554-25-NL. (2019)   pp,10.1186/isrctn95861172,,,,Missing EZProxy credentials.,unreachable,,na
9741195,EUCTR2019-001793-28-NL. Adalimumab dose reduction aiming low drug levels with control of disease activity (ADDORA-LOW). http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2019-001793-28-NL. (2019)   pp,10.31525/ct1-nct04222920,,,,Missing EZProxy credentials.,unreachable,,na
9262490,"Mease PJ; Chen S; Ganz F; Tillett W. Correlation of the routine assessment of patient index data (rapid-3) with other psoriatic arthritis composite disease activity measures in patients receiving adalimumab. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp682-683",10.1136/annrheumdis-2017-eular.1952,,,,Missing EZProxy credentials.,unreachable,,na
11083572,"Vadell Anna K E; Barebring Linnea; Hulander Erik; Gjertsson Inger; Lindqvist Helen M; Winkvist Anna. Anti-inflammatory Diet In Rheumatoid Arthritis (ADIRA)-a randomized, controlled crossover trial indicating effects on disease activity. American journal of clinical nutrition. (2020) 111 6 pp1203-1213",10.1093/ajcn/nqaa019,http://academic.oup.com/ajcn/article-pdf/111/6/1203/33325182/nqaa019.pdf,http://academic.oup.com/ajcn/article-pdf/111/6/1203/33325182/nqaa019.pdf,,,pdf,,Invalid
9258420,Emery P; Durez P; Dougados M; Legerton CW; Becker JC; Vratsanos G; Genant HK; Peterfy C; Mitra P; Overfield S; Qi K; Westhovens R. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Annals of the rheumatic diseases. (2010) 69 3 pp510-516,10.1136/ard.2009.119016,,,,Missing EZProxy credentials.,unreachable,,na
9740217,EUCTR2008-004398-16-SE. A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable RA Patients in Clinical remission - ADMIRE. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-004398-16-SE. (2008)   pp,10.1136/rmdopen-2015-000133,,https://rmdopen.bmj.com/rmdopen/2/1/e000133.full.pdf,,,pdf,,Page Not Found
9739966,EUCTR2015-003433-10-HU. ADMYRA Trial: clinical trial to compare treatment with GP2017 and Humira¬¨√Ü in patients with Rheumatoid Arthritis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-003433-10-HU. (2016)   pp,10.1186/isrctn25142273,,,,Missing EZProxy credentials.,unreachable,,na
9260300,Van Riel PLCM; Taggart AJ; Sany J; Gaubitz M; Nab HW; Pedersen R; Freundlich B; MacPeek D. Efficacy and safely of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Annals of the rheumatic diseases. (2006) 65 11 pp1478-1483,10.1136/ard.2005.043299,,,,Missing EZProxy credentials.,unreachable,,na
9260373,"Sennels H; S‚àö‚àèrensen S; Ostergaard M; Knudsen L; Hansen M; Skj‚àö‚àèdt H; Peters N; Colic A; Grau K; Jacobsen S. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scandinavian journal of rheumatology. (2008) 37 4 pp241-247",10.1080/03009740801910320,,,,Missing EZProxy credentials.,unreachable,,na
9263527,"Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; Van Der Heijde D; Miyasaka N; Koike T. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the rheumatic diseases. (2016) 75  1 pp75-83",10.1136/annrheumdis-2015-207511,,,,Missing EZProxy credentials.,unreachable,,na
9262475,"Jansen D; Emery P; Smolen J; Westhovens R; Le Bars M; Connolly S; Ye J; Toes R; Huizinga T. Association between conversion to ACPA/RF seronegative status and clinical outcomes following treatment with abatacept in combination with methotrexate compared with methotrexate alone in patients with early rheumatoid arthritis and poor prognostic indicators. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp566",10.1136/annrheumdis-2017-eular.1716,,,,Missing EZProxy credentials.,unreachable,,na
9736634,Westhovens R; Wollenhaupt J; Haraoui B; Becker J C; Covucci A; Rosenblatt L; Bathon J. Sustained and clinically meaningful improvements in physical function and fatigue and Reductions in activity limitation are observed in MTX-nave patients with early rheumatoid arthritis (RA) treated with abatacept over 2 years of the AGREE trial. Arthritis and rheumatism. (2010) 62 SUPPL. 10 pp1837,10.1016/s0973-3698(09)60080-7,,,,Missing EZProxy credentials.,unreachable,,na
9738276,Jansen DTSL; Emery P; Smolen JS; Westhovens R; Le Bars M; Connolly SE; Ye J; Toes REM; Huizinga TWJ. Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD open. (2018) 4 1 pp,10.1136/rmdopen-2017-000564,,https://rmdopen.bmj.com/rmdopen/4/1/e000564.full.pdf,,,pdf,,Page Not Found
9738897,Haraoui B; Westhovens R; Robles M; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Shergy W; Park S; Genant H; Peterfy C; Becker J C; Covucci A; Helfrick R; Bathon J. The efficacy and safety of abatacept in methotrexate-naive patients with early erosive rheumatoid arthritis and poor prognostic factors. Journal of rheumatology. (2009) 36 11 pp2593,10.1136/ard.2008.101121,,,,Missing EZProxy credentials.,unreachable,,na
9739013,"Westhovens R; Durez P; Genant H; Robles M; Becker J C; Covucci A; Bathon J. Disease remission, normalized physical function and radiographic non-progression are achieved by the majority of patients with early rheumatoid arthritis (RA) treated with abatacept (ABA) + methotrexate (MTX): results from the 2-year agree trial. Journal of rheumatology. (2011) 38 6 pp1197-1198",10.1136/ard.2010.145268,,,,Missing EZProxy credentials.,unreachable,,na
9258151,Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechi‚âà√ëski J; Li T; Teng J; Becker JC; Westhovens R. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis and rheumatism. (2008) 58 4 pp953-963,10.1002/art.23397,,,,Missing EZProxy credentials.,unreachable,,na
9260311,Genant HK; Peterfy CG; Westhovens R; Becker JC; Aranda R; Vratsanos G; Teng J; Kremer JM. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Annals of the rheumatic diseases. (2008) 67 8 pp1084-1089,10.1136/ard.2007.085084,,,,Missing EZProxy credentials.,unreachable,,na
9260603,Vecchio P; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Zhao C; Becker JC; Westhovens R; Kremer JM. The AIM trial: four-year safety and efficacy of abatacept in rheumatoid arthritis patients with inadequate response to methotrexate [Abstract]. Internal medicine journal. (2009) 39 S2 ppA73,10.1136/ard.2010.139345,,,,Missing EZProxy credentials.,unreachable,,na
9261160,Sibilia J; Flipo RM; Combe B; Gaillez C; Le Bars M; Poncet C; Elegbe A; Westhovens R. Abatacept confers clinical efficacy regardless of baseline CRP status in patients with rheumatoid arthritis and inadequate response to methotrexate in the aim trial. Rheumatology (United Kingdom). (2012) 51  ppiii124-iii125,10.1136/annrheumdis-2012-eular.2656,,,,Missing EZProxy credentials.,unreachable,,na
9263168,Russell AS; Wallenstein GV; Li T; Martin MC; Maclean R; Blaisdell B; Gajria K; Cole JC; Becker JC; Emery P. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the rheumatic diseases. (2007) 66 2 pp189-194,10.1136/ard.2006.057018,,,,Missing EZProxy credentials.,unreachable,,na
9738926,Kremer J M; Russell A S; Emery P; Abud-Mendoza C; Szechinski J; Becker J C; Wu G; Westhovens R. Abatacept demonstrates consistent safety and sustained improvements in efficacy through 5 years of treatment in biologic-naive patients with rheumatoid arthritis. Rheumatology. (2010) 49 SUPPL. 1 pp,10.1016/s0973-3698(09)60050-9,,,,Missing EZProxy credentials.,unreachable,,na
9739082,Haraoui P; Genant H K; Peterfy C; Westhovens R; Becker J C; Vratsanos G; Tsai K; Zhou X; Kremer J. Abatacept provides an increasing degree of inhibition of structural damage progression through 3 years in patients with rheumatoid arthritis and an inadequate response to methotrexate who remain on treatment. Journal of rheumatology. (2009) 36 11 pp2569,10.1016/s0973-3698(09)60049-2,,,,Missing EZProxy credentials.,unreachable,,na
9260626,"Wells G; Li T; Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Annals of the rheumatic diseases. (2010) 69 10 pp1768-1773",10.1136/ard.2009.119727,,,,Missing EZProxy credentials.,unreachable,,na
9738493,"Wells G; Li T; Maxwell L; MacLean R; Tugwell P.. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of rheumatology. (2007) 34 2 pp280-289",10.1136/ard.2007.069690,,,,Missing EZProxy credentials.,unreachable,,na
9261070,Huizinga T; Nigrovic P; Ruderman E; Schulze-Koops H. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: A post hoc analysis of randomized clinical trial data - Commentary. International Journal of Advances in Rheumatology. (2011) 9  4 pp150-151,10.1093/rheumatology/kew144.014,http://academic.oup.com/rheumatology/article-pdf/55/suppl_1/i97/5079008/kew144.014.pdf,http://academic.oup.com/rheumatology/article-pdf/55/suppl_1/i97/5079008/kew144.014.pdf,,,pdf,,Article
9260811,Alam MK; Sutradhar SR; Pandit H; Ahmed S; Bhattacharjee M; Miah AH; Bari MA; Islam MZ; Khan NA; Zannat KF; Akhter S. Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis. Mymensingh medical journal : MMJ. (2012) 21 3 pp391-398,10.3329/mmj.v15i2.46,,,,Missing EZProxy credentials.,unreachable,,na
11085300,Winthrop Kevin L; Harigai Masayoshi; Genovese Mark C; Lindsey Stephen; Takeuchi Tsutomu; Fleischmann Roy; Bradley John D; Byers Nicole L; Hyslop David L; Issa Maher; Nishikawa Atsushi; Rooney Terence P; Witt Sarah; Dickson Christina L; Smolen Josef S; Dougados Maxime. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the rheumatic diseases. (2020) 79 10 pp1290-1297,10.1136/annrheumdis-2019-216852,,,,Missing EZProxy credentials.,unreachable,,na
11086650,Hall S; Genovese MC; Smolen JS; Takeuchi T; Burmester G; Brinker D; Rooney TP; Zhong J; Mo D; Saifan C; Cardoso A; Issa M; Wu W-S; Winthrop KL. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Internal medicine journal. (2020) 50 SUPPL 2 pp16,10.1136/annrheumdis-2019-eular.691,,,,Missing EZProxy credentials.,unreachable,,na
9261233,"Kaine J; Gladstein G; Strusberg I; Robles M; Pappu R; Delaet I; Pans M; Ludivico C. Subcutaneous (SC) abatacept is well tolerated, demonstrates clinical efficacy and is associated with low immunogenicity following withdrawal and re-introduction: Phase III evaluation in rheumatoid arthritis (RA) patients responding to abatacept. Zeitschrift fur Rheumatologie. (2011) 70  pp87-88",10.1136/annrheumdis-2011-200344,,,,Missing EZProxy credentials.,unreachable,,na
9741019,NCT00533897. Phase IIIB Subcutaneous Missed Dose Study. https://clinicaltrials.gov/show/NCT00533897. (2007)   pp,10.1179/175709310x12845438122791,,,,Missing EZProxy credentials.,unreachable,,na
9741066,NCT01225393. A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis. https://clinicaltrials.gov/show/NCT01225393. (2010)   pp,10.1007/978-3-211-79280-3_256,http://link.springer.com/content/pdf/10.1007/978-3-211-79280-3_256.pdf,http://link.springer.com/content/pdf/10.1007/978-3-211-79280-3_256.pdf,,,pdf,,Article
9737415,"Mazurov V; Denisov L; Gordeev I; Nesmeyanova O; Plaksina T; Ilivanova E; Krechikova D; Zonova E; Knyazeva L; Artemeva A; Dokukina E; Chernyaeva E; Ivanov R. Results of the alterra clinical trial-the efficacy of the alternative dosing regimen for rituximab biosimilar in bDMARDS naive patients with rheumatoid arthritis. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp963",10.1136/annrheumdis-2018-eular.2300,,,,Missing EZProxy credentials.,unreachable,,na
9262476,"Kohm M; Rossmanith T; Dauth S; Alten R; Aringer M; Backhaus M; Burmester G; Feist E; Kellner H; Kruger K; Muller-Ladner U; Rubbert-Roth A; Tony H-P; Wassenberg S; Burkhardt H; Behrens F. Impact of rituximab in combination with leflunomide and rituximab retreatment with two different dosages on patient-reported outcomes: results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (amara-study). Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp565",10.1136/annrheumdis-2017-eular.6238,,,,Missing EZProxy credentials.,unreachable,,na
9737502,Behrens F; Rossmanith T; Kohm M; Alten R; Aringer M; Backhaus M; Baerwald C; Burmester G; Feist E; Kellner H; Kruger K; Muller-Ladner U; Rubbert-Roth A; Tony H-P; Wassenberg S; Burkhardt H. Rituximab in combination with leflunomide: results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-study). Annals of the rheumatic diseases. (2016) 75  pp502-,10.1136/annrheumdis-2016-eular.5684,,,,Missing EZProxy credentials.,unreachable,,na
9738820,Behrens F; Rossmanith T; Kohm M; Alten R; Aringer M; Backhaus M; Baerwald C; Burmester G; Feist E; Kellner H; Kruger K; Muller-Ladner U; Rubbert-Roth A; Tony H P; Wassenberg S; Burkhardt H. Rituximab in combination with leflunomide: results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-study). Annals of the rheumatic diseases. (2016) 75 Supplement 2 pp502,10.1136/annrheumdis-2016-eular.5684,,,,Missing EZProxy credentials.,unreachable,,na
11085150,"Koehm M; Foldenauer AC; Rossmanith T; Alten R; Aringer M; Backhaus M; Burmester GR; Feist E; Kellner H; Krueger K; Muller-Ladner U; Rubbert-Roth A; Tony H-P; Wassenberg S; Burkhardt H; Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). Journal of clinical medicine. (2022) 11 24 pp",10.3390/jcm11247316,,,,Missing EZProxy credentials.,unreachable,,na
9258318,Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert review of clinical immunology. (2010) 6 2 pp189-195,10.1586/eci.10.2,,,,Missing EZProxy credentials.,unreachable,,na
9261100,Jones G; Taylor A; Sebba A; Anisfeld A; Devenport J; Bernasconi C; Smart D; Galindez D; Mpofu C; Gomez-Reino J. Long-term efficacy of tocilizumab (TCZ) monotherapy in patients with rheumatoid arthritis (RA) previously methotrexate (MTX) naive or MTX free for 6 months. Internal medicine journal. (2013) 43  pp12,10.1136/annrheumdis-2013-eular.1375,,,,Missing EZProxy credentials.,unreachable,,na
9738350,NCT00109408. A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis. https://clinicaltrials.gov/show/NCT00109408. (2005)   pp,10.1007/s10165-011-0419-6,,,,Missing EZProxy credentials.,unreachable,,na
9742233,"Bay-Jensen AC; Siebuhr AS; Thudium CS; Karsdal MA. Tissues are differently modulated by tocilizumab and methotrexate; assessment of connective tissue metabolites in the ambition study. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp551",10.1136/annrheumdis-2018-eular.6945,,,,Missing EZProxy credentials.,unreachable,,na
9737014,"Safy M; Jacobs JWG; Edwardes M; De Hair MJH; Teitsma XM; Welsing PMJ; Borm MEA; Luder Y; Van Laar J; Petho-Schramm A; Bijlsma JWJ. No effect of concomitant glucocorticoid therapy on efficacy and safety of tocilizumab monotherapy found in rheumatoid arthritis clinical trials. Arthritis and rheumatology. (2018) Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 2018. United States. 70 Supplement 9 pp1719-1720",10.1136/annrheumdis-2018-eular.6327,,,,Missing EZProxy credentials.,unreachable,,na
9738711,"Safy M; Jacobs JWG; Edwardes M; Pei J; De Hair M; Teitsma X; Welsing P; Borm M; Luder Y; Van Laar J; Petho-Schramm A; Bijlsma JWJ. No evidence that concomitant glucocorticoid therapy affects efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trials. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp945",10.1136/annrheumdis-2018-eular.6327,,,,Missing EZProxy credentials.,unreachable,,na
9741219,Collins JE; Johansson FD; Gale S; Kim S; Shrestha S; Sontag D; Stratton J; Trinh H; Xu C; Losina E; Solomon DH. Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: model Derivation and Remission Score Development. ACR open rheumatology. (2020)   pp,10.1002/acr2.11101,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11101,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11101,,,html,,PDF
9741603,Collins Jamie E; Johansson Fredrik D; Gale Sara; Kim Seoyoung; Shrestha Swastina; Sontag David; Stratton Jacklyn; Trinh Huong; Xu Chang; Losina Elena; Solomon Daniel H. Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: model Derivation and Remission Score Development. ACR open rheumatology. (2020) 2 2 pp65-73,10.1002/acr2.11101,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11101,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11101,,,html,,PDF
9742353,"Collins J; Johansson F; Gale S; Kim S; Shrestha S; Sontag D; Stratton J; Huong T; Xu C; Losina E; Solomon D. Predicting remission among patients with rheumatoid arthritis starting tocilizumab monotherapy: model derivation and validation using conventional regression and machine learning. Annals of the rheumatic diseases. (2019) Conference: Annual European Congress of Rheumatology, EULAR 2019. Spain. 78 Supplement 2 pp727",10.1136/annrheumdis-2019-eular.4305,,,,Missing EZProxy credentials.,unreachable,,na
9257684,"Strand V; Lampl K; Birchwood C; Pei J; Tuckwell K; Finch R; Gabay C; Kavanaugh A; Jones G. Patient-reported outcomes in two randomized, controlled trials (RCTS) in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ) monotherapy compared with methotrexate (MTX) or adalimumab (ADA). Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp3356-3359",10.1136/rmdopen-2017-000496,,https://rmdopen.bmj.com/rmdopen/3/2/e000496.full.pdf,,,pdf,,Page Not Found
9736488,"Fautrel B; Zhu B; Taylor PC; Van De Laar M; Emery P; De Leonardis F; Gaich C; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R. Comparative effectiveness in pain and HAQ-DI improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in cSDMARD-naive rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC). Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp973-974",10.1136/annrheumdis-2018-eular.1997,,,,Missing EZProxy credentials.,unreachable,,na
9261386,Genovese MC; Kremer JM; Van Vollenhoven RF; Alten R; Scali JJ; Kelman A; Rowell L; Pitts L. Transaminase levels and hepatic events observed during tocilizumab treatment: Pooled analysis of long-term clinical trial safety data in patients with rheumatoid arthritis. Arthritis and rheumatism. (2013) 65  ppS201,10.1002/art.40176,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.40176,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.40176,,,html,,Page Not Found
9739081,Haraoui B; Van Vollenhoven; R F; Smolen J S. Safety of tocilizumab in patients with rheumatoid arthritis: an interim analysis of long-term extension trials with a mean treatment duration of 1.5 years. Journal of rheumatology. (2009) 36 11 pp2596,10.1136/annrheumdis-2013-eular.1383,,,,Missing EZProxy credentials.,unreachable,,na
9260757,"Weinblatt ME; Schiff M; Valente R; van der Heijde D; Citera G; Zhao C; Maldonado M; Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and rheumatism. (2013) 65 1 pp28-38",10.1002/art.37711,https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.37711,https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.37711,,,html,,PDF
9261112,Weinblatt ME; Schiff MH; Fleischmann R; Valente R; Van Der Heijde D; Citera G; Zhao C; Maldonado MA. Head to head comparison of subcutaneous abatacept versus adalimumab in the treatment of rheumatoid arthritis: Key efficacy and safety results from the ample (abatacept versus adalimumab comparison in biologic-naive RA subjects with background methotrexate) trial. Arthritis and rheumatism. (2012) 64  ppS1031,10.1093/rheumatology/keu101.007,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i88/9578452/keu101.007.pdf,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i88/9578452/keu101.007.pdf,,,pdf,,Article
9261121,Fleischmann R; Schiff MH; Weinblatt ME; Maldonado MA; Massarotti EM; Yazici Y. Effects of subcutaneous abatacept or adalimumab on remission and associated changes in physical function and radiographic outcomes: One year results from the ample (abatacept versus adalimumab comparison in biologic-naive ra subjects with background methotrexate) trial. Arthritis and rheumatism. (2012) 64  ppS577,10.1136/annrheumdis-2013-eular.1858,,,,Missing EZProxy credentials.,unreachable,,na
9261289,Maldonado M; Fleischmann R; Weinblatt M; Schiff M; Khanna D; Furst D. Changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis: Results from the ample (abatacept versus adalimumab comparison in biologic-naive ra subjects with background methotrexate) trial. Journal of rheumatology. (2013) 40  6 pp1006,10.1136/annrheumdis-2014-eular.2113,,,,Missing EZProxy credentials.,unreachable,,na
9261306,Weinblatt ME; Schiff MH; Valente R; Van Der Heijde D; Citera G; Elegbe A; Maldonado MA; Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab on background methotrexate in rheumatoid arthritis: Blinded two-year results from the ample study. Rheumatology (United Kingdom). (2014) 53  ppi88,10.1093/rheumatology/keu101.007,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i88/9578452/keu101.007.pdf,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i88/9578452/keu101.007.pdf,,,pdf,,PDF
9261313,"Fleischmann R; Weinblatt M; Schiff M; Khanna D; Rosenblatt L; Maldonado M; Furst D. Improved quality of life, work productivity, general activity and independence in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis: Results from the ample trial. Annals of the rheumatic diseases. (2013) 72  pp",10.1136/annrheumdis-2013-eular.1855,,,,Missing EZProxy credentials.,unreachable,,na
9261392,Fleischmann R; Weinblatt ME; Schiff M; Khanna D; Maldonado MA; Nadkarni A; Furst DE. 2-Year results from the ample (abatacept versus adalimumab comparison in biologic-naive RA patients with background methotrexate) trial: Changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis. Arthritis and rheumatism. (2013) 65  ppS183,10.1136/annrheumdis-2014-eular.2113,,,,Missing EZProxy credentials.,unreachable,,na
9261886,Charles-Schoeman C; Gugiu GB; Ge H; Shahbazian A; Lee YY; Wang X; Furst DE; Ranganath VK; Maldonado M; Reddy ST. Proteomic profiling following immunoaffinity capture of high-density lipoprotein (HDL) identifies changes in multiple hdl-associated proteins following treatment with abatacept or adalimumab in the ample study of patients with rheumatoid arthritis. Annals of the rheumatic diseases. (2015) 74  pp443,10.1136/annrheumdis-2015-eular.2330,,,,Missing EZProxy credentials.,unreachable,,na
9262605,Charles-Schoeman C; Gugiu GB; Ge H; Shahbazian A; Lee YY; Wang X; Furst DE; Ranganath VK; Maldonado M; Lee T; Reddy ST. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis. (2018) 275  pp107-114,10.1016/j.atherosclerosis.2018.04.003,,,,Missing EZProxy credentials.,unreachable,,na
9738599,"Foo J; Rodriguez-Heredia JMR; Sanchez CP; Mtibaa M; Herrmann KH; Alemao E; Postema R; Baerwald C. Cost per response for abatacept versus adalimumab in patients with seropositive erosive, early rheumatoid arthritis in the United States, DEU, ESP and CAN. Rheumatology (united kingdom). (2018) Conference: 2018 Annual Conference of the British Society for Rheumatology. United Kingdom. 57 Supplement 3 ppiii136-iii137",10.1093/rheumatology/key075.444,http://academic.oup.com/rheumatology/article-pdf/57/suppl_3/key075.444/24768364/key075.444.pdf,http://academic.oup.com/rheumatology/article-pdf/57/suppl_3/key075.444/24768364/key075.444.pdf,,,pdf,,PDF
9742497,Charles-Schoeman C; Gugiu G B; Ge H; Shahbazian A; Lee Y Y; Wang X; Furst D E; Ranganath V K; Maldonado M; Lee Terry; Reddy S T. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis. Atherosclerosis. (2018) 275  pp107-114,10.1016/j.atherosclerosis.2018.04.003,,,,Missing EZProxy credentials.,unreachable,,na
11085578,Degboe Y; Schiff M; Weinblatt M; Fleischmann R; Ahmad HA; Constantin A. Background glucocorticoid therapy has no impact on efficacy and safety of abatacept or adalimumab in patients with rheumatoid arthritis. Journal of clinical medicine. (2020) 9 6 pp1-9,10.3390/jcm9062017,,,,Missing EZProxy credentials.,unreachable,,na
11086593,Klink A; Han X; Lobo F; Szymialis R; Lam J; Feinberg B. Clinical benefits reported in ample trial observed in a real-world (RW) cohort of us rheumatoid arthritis (RA) patients. Annals of the rheumatic diseases. (2020) 79 SUPPL 1 pp626-627,10.1136/annrheumdis-2020-eular.1453,,,,Missing EZProxy credentials.,unreachable,,na
9740616,. Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/ double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials. Clinical and experimental rheumatology. (2019) 37 1 pp127-132,10.1093/rheumatology/kew144.015,http://academic.oup.com/rheumatology/article-pdf/55/suppl_1/i98/5079020/kew144.015.pdf,http://academic.oup.com/rheumatology/article-pdf/55/suppl_1/i98/5079020/kew144.015.pdf,,,pdf,,Article
9259003,"Andersen PA; West SG; O'Dell JR; Via CS; Claypool RG; Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Annals of internal medicine. (1985) 103 4 pp489-496",10.7326/0003-4819-103-4-489,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-103-4-489,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-103-4-489,,,html,,Article
9739757,EUCTR2016-000335-40-BG. A Study examining the treatment effect and Safety of GDC-0853 when compared With Placebo and a biologic therapy (Adalimumab) in Rheumatoid Arthritis Patients who have not responded or intolerance to Previous therapies. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2016-000335-40-BG. (2016)   pp,10.1186/isrctn63375144,,,,Missing EZProxy credentials.,unreachable,,na
11084444,"Cohen S; Tuckwell K; Katsumoto TR; Zhao R; Galanter J; Lee C; Rae J; Toth B; Ramamoorthi N; Hackney JA; Berman A; Damjanov N; Fedkov D; Jeka S; Chinn LW; Townsend MJ; Morimoto AM; Genovese MC. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: a Randomized, Double-Blind, Phase II Trial (ANDES Study). . (2020)   pp",10.1002/art.41275,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.41275,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.41275,,,html,,Page Not Found
9260828,Kim HY; Hsu PN; Barba M; Sulaiman W; Robertson D; Vlahos B; Khandker R; Nab H; Freundlich B; Koenig A. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. International journal of rheumatic diseases. (2012) 15 2 pp188-196,10.1111/j.1756-185x.2011.01680.x,,,,Missing EZProxy credentials.,unreachable,,na
9261652,"Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Rheumatology (Oxford, England). (2014) 53 11 pp1984-1993",10.1093/rheumatology/keu235,http://academic.oup.com/rheumatology/article-pdf/53/11/1984/17388453/keu235.pdf,http://academic.oup.com/rheumatology/article-pdf/53/11/1984/17388453/keu235.pdf,,,pdf,,Article
9739576,"EUCTR2014-000109-11-BG. Study to assess the efficacy and safety of FKB327 compared with Humira¬¨√Ü, when each is administered in combination with Methotrexate in patients with Rheumatoid Arthritis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014-000109-11-BG. (2014)   pp",10.31525/ct1-nct04230213,,,,Missing EZProxy credentials.,unreachable,,na
9737692,Nordberg Lena Bugge; Lillegraven Siri; Aga Anna-Birgitte; Sexton Joseph; Olsen Inge Christoffer; Lie Elisabeth; Berner Hammer Hilde; Uhlig Till; van der Heijde Desiree; Kvien Tore K; Haavardsholm Espen A. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD open. (2018) 4 2 ppe000752,10.1136/rmdopen-2018-000752,,https://rmdopen.bmj.com/rmdopen/4/2/e000752.full.pdf,,,pdf,,Page Not Found
9741017,NCT01205854. Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial. https://clinicaltrials.gov/show/NCT01205854. (2010)   pp,10.1007/bf03318142,http://link.springer.com/article/10.1007/BF03318142/fulltext.html,http://link.springer.com/article/10.1007/BF03318142/fulltext.html,,,html,,Article
9742136,"Holten K; Sexton J; Kvien TK; Haavardsholm EA; Aga A-B. Comparative analyses of responsiveness between the rheumatoid arthritis impact of disease (RAID) score, other patient reported outcomes and disease activity measures: secondary analyses from the arctic study. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp1824",10.1136/annrheumdis-2018-eular.2889,,,,Missing EZProxy credentials.,unreachable,,na
9743066,"Sundin Ulf; Aga Anna-Birgitte; Skare Oivind; Nordberg Lena B; Uhlig Till; Hammer Hilde B; van der Heijde Desiree; Kvien Tore K; Lillegraven Siri; Haavardsholm Espen A; ARCTIC study group. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology (Oxford, England). (2020)   pp",10.1093/rheumatology/kez674,http://academic.oup.com/rheumatology/article-pdf/59/9/2550/33686414/kez674.pdf,http://academic.oup.com/rheumatology/article-pdf/59/9/2550/33686414/kez674.pdf,,,pdf,,Article
11085077,Paulshus Sundlis√¶ter N; Sundin U; Aga AB; Sexton J; Hammer HB; Uhlig T; Kvien TK; Haavardsholm EA; Lillegraven S. Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. . (2022) 8 1 pp,10.1136/rmdopen-2021-002013,,https://rmdopen.bmj.com/rmdopen/8/1/e002013.full.pdf,,,pdf,,Page Not Found
11085658,Holten K; Paulshus Sundlisater N; Lillegraven S; Sexton J; Nordberg LB; Moholt E; Hammer HB; Uhlig T; Kvien TK; Haavardsholm EA; Aga AB. Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. Annals of the rheumatic diseases. (2022) 81 3 pp344-350,10.1136/annrheumdis-2021-220750,,,,Missing EZProxy credentials.,unreachable,,na
11086603,"Lillegraven S; Sundlisaeter NP; Aga AB; Sexton J; Olsen I; Lexberg A; Madland TM; Fremstad H; Hoili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon D; Van Der Heijde D; Kvien TK; Haavardsholm EA. Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission (Arctic Rewind): a randomised, open-label, phase 4, non-inferiority trial. Annals of the rheumatic diseases. (2020) 79 SUPPL 1 pp14-15",10.1136/annrheumdis-2020-eular.1955,,,,Missing EZProxy credentials.,unreachable,,na
9260171,Weinblatt ME; Keystone EC; Furst DE; Kavanaugh AF; Chartash EK; Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Annals of the rheumatic diseases. (2006) 65 6 pp753-759,10.1136/ard.2005.044404,,,,Missing EZProxy credentials.,unreachable,,na
9740499,. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology. (2004) 43 6 pp712-718,10.1093/rheumatology/keh153,http://academic.oup.com/rheumatology/article-pdf/43/6/712/9445317/keh153.pdf,http://academic.oup.com/rheumatology/article-pdf/43/6/712/9445317/keh153.pdf,,,pdf,,Article
9257732,"Yount S; Sorensen MV; Cella D; Sengupta N; Grober J; Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clinical and experimental rheumatology. (2007) 25 6 pp838-846",10.1093/rheumatology/keh153,http://academic.oup.com/rheumatology/article-pdf/43/6/712/9445317/keh153.pdf,http://academic.oup.com/rheumatology/article-pdf/43/6/712/9445317/keh153.pdf,,,pdf,,Article
9257967,"Alheresh R; Allaire SH; Lavalley MP; Vaughan M; Emmetts R; Keysor JJ. ""Work it"" recruitment: Lessons learned from an arthritis work disability prevention randomized trial. Arthritis and rheumatism. (2013) 65  ppS1220",10.1016/j.conctc.2021.100862,,,,Missing EZProxy credentials.,unreachable,,na
9256861,Smolen JS; Han C; van der Heijde DM; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Aletaha D; Baker D; Han J; Bala M; St Clair EW; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Annals of the rheumatic diseases. (2009) 68 6 pp823-827,10.1136/ard.2008.090019,,,,Missing EZProxy credentials.,unreachable,,na
9258557,Smolen JS; Van Der Heijde DM; St Clair EW; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Schiff M; Baker D; Han C; Han J; Bala M; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis and rheumatism. (2006) 54 3 pp702-710,10.1002/art.21678,,,,Missing EZProxy credentials.,unreachable,,na
9260380,Bejarano V; Quinn M; Conaghan PG; Reece R; Keenan AM; Walker D; Gough A; Green M; McGonagle D; Adebajo A; Jarrett S; Doherty S; Hordon L; Melsom R; Unnebrink K; Kupper H; Emery P; Yorkshire Early Arthritis Register Consortium. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis and rheumatism. (2008) 59 10 pp1467-1474,10.1002/art.24106,,,,Missing EZProxy credentials.,unreachable,,na
9260494,Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Annals of the rheumatic diseases. (2009) 68 10 pp1535-1540,10.1136/ard.2008.094128,,,,Missing EZProxy credentials.,unreachable,,na
9263423,Moreland L. Efficacy of costimulation blockade with abatacept in rheumatoid arthritis patients refractory to tumor necrosis factor-alpha inhibition. Current rheumatology reports. (2006) 8  5 pp367,10.1007/s11926-006-0066-7,http://link.springer.com/article/10.1007/s11926-006-0066-7/fulltext.html,http://link.springer.com/article/10.1007/s11926-006-0066-7/fulltext.html,,,html,,Article
9738463,Strand V; Purcaru O; Kavanaugh A. Work productivity measures as treatment goals beyond signs and symptoms. Arthritis and rheumatism. (2009) 60  pp64-,10.1002/art.24828,,,,Missing EZProxy credentials.,unreachable,,na
9260808,"Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Annals of the rheumatic diseases. (2013) 72 8 pp1287-1294",10.1136/annrheumdis-2012-201611,,,,Missing EZProxy credentials.,unreachable,,na
9737286,"EUCTR2006-003768-67-SE. A Phase III Multicenter, Randomized, Double-Blind, placebo-controlled Study to Assess short-term changes in synovitis and structural damage outcomes in subjects with active Rheumatoid Arthritis and inadequate response to Methotrexate, Treated with Abatacept versus Placebo on a Background Therapy with Methotrexate  Revised Protocol 03, incorporating Protocol Amendment 01 (Version 1.0, Date 16-May-2007), Protocol Amendment 03 (Version 1.0, Date 19-Mar-2008), Protocol Amendment 04 (Version 1.0, Date 05-Dec-2008), and Administrative Letter dated 13-Jun-2007. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-003768-67-SE. (2007)   pp",10.3410/f.1097731.553845,,,,Missing EZProxy credentials.,unreachable,,na
9739801,EUCTR2012-003876-38-PL. Clinical study to find out if the biologically similar medicine GP2013 is safe in patients with rheumatoid arthritis who have been treated with Rituxan¬¨√Ü or MabThera¬¨√Ü in the past. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-003876-38-PL. (2015)   pp,10.1111/1756-185x.15055,,,,Missing EZProxy credentials.,unreachable,,na
9257458,Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Annals of the rheumatic diseases. (2008) 67 4 pp547-554,10.1136/ard.2007.074773,,,,Missing EZProxy credentials.,unreachable,,na
9260230,"Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford, England). (2006) 45 10 pp1238-1246",10.1093/rheumatology/kel066,http://academic.oup.com/rheumatology/article-pdf/45/10/1238/6698111/kel066.pdf,http://academic.oup.com/rheumatology/article-pdf/45/10/1238/6698111/kel066.pdf,,,pdf,,Article
9260347,Fernandez-Lopez C; Blanco FJ. ATTAIN study: Efficacy of abatacept in patients with rheumatoid arthritis and inadequate response to anti-TNF-alpha. [Spanish]. Reumatologia Clinica Suplementos. (2006) 1 2 pp34-43,10.1093/rheumatology/kes115,http://academic.oup.com/rheumatology/article-pdf/51/suppl_5/v22/5055090/kes115.pdf,http://academic.oup.com/rheumatology/article-pdf/51/suppl_5/v22/5055090/kes115.pdf,,,pdf,,Article
9256934,Atteritano M; Mazzaferro S; Mantuano S; Bagnato GL; Bagnato GF. Effects of infliximab on sister chromatid exchanges and chromosomal aberration in patients with rheumatoid arthritis. Cytotechnology. (2016) 68  2 pp313-318,10.1007/s10616-014-9782-4,http://link.springer.com/article/10.1007/s10616-014-9782-4/fulltext.html,http://link.springer.com/article/10.1007/s10616-014-9782-4/fulltext.html,,,html,,Article
9260771,Benucci M; Stam WB; Gilloteau I; Sennf‚àö¬ßlt K; Leclerc A; Maetzel A; Lucioni C. Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis. Clinical and experimental rheumatology. (2013) 31 4 pp575-583,10.1016/j.jval.2011.08.415,,,,Missing EZProxy credentials.,unreachable,,na
9737050,"EUCTR2004-000922-59-SE. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects with Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate.  Revised Protocol 1 , incorporating Amendment 02 (v5.0).  Pharmacogenomic Amendment 01.  Protocol Amendment 03 - Long-Term Extension.  Protocol Amendment 05 - Long Term Extension Site Specific (V2.0, Date 23-Dec-2006). http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2004-000922-59-SE. (2004)   pp",10.3410/f.1097731.553845,,,,Missing EZProxy credentials.,unreachable,,na
9741012,NCT00095147. Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis. https://clinicaltrials.gov/show/NCT00095147. (2004)   pp,10.1093/rheumatology/kev080.006,http://academic.oup.com/rheumatology/article-pdf/54/suppl_1/i28/5179183/kev080.006.pdf,http://academic.oup.com/rheumatology/article-pdf/54/suppl_1/i28/5179183/kev080.006.pdf,,,pdf,,Article
9257449,Lipsky PE; Van Der Heijde DMFM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New England journal of medicine. (2000) 343 22 pp1594-1602,10.1056/nejm200011303432202,,,,Missing EZProxy credentials.,unreachable,,na
9258511,"St Clair EW; Wagner CL; Fasanmade AA; Wang B; Schaible T; Kavanaugh A; Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and rheumatism. (2002) 46 6 pp1451-1459",10.1002/art.10302,,,,Missing EZProxy credentials.,unreachable,,na
9260069,Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis and rheumatism. (2005) 52 4 pp1020-1030,10.1002/art.20982,,,,Missing EZProxy credentials.,unreachable,,na
9737564,Wong J B; Singh G; Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. American journal of medicine. (2002) 113 5 pp400-408,10.1016/s0002-9343(02)01243-3,,,,Missing EZProxy credentials.,unreachable,,na
9739793,ISRCTN51200229. Randomised double blind trial of safety of anti-tumour necrosis factor (anti-TNF) chimeric monoclonal antibody (infliximab) in combination with methatrexate compared to methatrexate alone in patients with rheumatoid arthritis on standard disease modifying anti-rheumatic drugs. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN51200229. (2003)   pp,10.1186/isrctn51200229,,,,Missing EZProxy credentials.,unreachable,,na
9741042,NCT00430495. A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I). https://clinicaltrials.gov/show/NCT00430495. (2007)   pp,10.1002/art.23178,,,,Missing EZProxy credentials.,unreachable,,na
9260702,"van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis and rheumatism. (2011) 63 7 pp1782-1792",10.1002/art.30372,,,,Missing EZProxy credentials.,unreachable,,na
11085520,"Mazurov V; Zotkin E; Ilivanova E; Kropotina T; Plaksina T; Nesmeyanova O; Soroka N; Kundzer A; Lutskii A; Dokukina E; Eremeeva A; Zinkina-Orihan A. Efficacy of levilimab, novel monoclonal anti-IL-6 receptor antibody, in combination with methotrexate in patients with rheumatoid arthritis: 1-year results of phase 2 aurora study. Annals of the rheumatic diseases. (2020) 79 SUPPL 1 pp637-638",10.1136/annrheumdis-2020-eular.5465,,,,Missing EZProxy credentials.,unreachable,,na
9261842,"Furst DE; Bykerk VP; Burmester GR; Combe BG; Huizinga TWJ; Alemao E; Wong DA; Emery P. Treatment effects and minimal clinically important differences in patient-reported outcomes following treatment and withdrawal of abatacept, methotrexate or combination therapy in patients with early rheumatoid arthritis. Annals of the rheumatic diseases. (2015) 74  pp1044",10.1136/annrheumdis-2015-eular.1463,,,,Missing EZProxy credentials.,unreachable,,na
9262220,"Peterfy C; Burmester GR; Bykerk VP; Combe BG; DiCarlo JC; Furst DE; Huizinga TW; Wong DA; Conaghan PG; Emery P. Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the rheumatic diseases. (2016) 75 8 pp1501-1505",10.1136/annrheumdis-2015-208258,,,,Missing EZProxy credentials.,unreachable,,na
9261955,"Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Peth‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚Äö√Ñ‚Ä†‚Äö√†√∂‚Äö√†√á‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚Äö√Ñ‚Ä†‚Äö√†√∂‚àö¬∞-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (u-act-early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet (london, england). (2016) 388 10042 pp343-355",10.1016/s0140-6736(16)30363-4,,,,Missing EZProxy credentials.,unreachable,,na
9736943,Ahmad HA; Baker JF; Ostergaard M; Ye J; Emery P; Conaghan PG. Validating MRI-detected inflammation thresholds predictive of structural damage progression in patients with rheumatoid arthritis in a randomized placebo-controlled trial. Annals of the rheumatic diseases. (2016) 75  pp624-,10.1136/annrheumdis-2016-eular.1374,,,,Missing EZProxy credentials.,unreachable,,na
9739060,Emery P; Burmester G; Bykerk V; Combe B; Furst D E; Maldonado M A; Huizinga T W. Abatacept plus methotrexate can effectively and safely regain the target of remission following re-treatment for flares after drug-free withdrawal in patients with early rheumatoid arthritis. Annals of the rheumatic diseases. (2016) 75 Supplement 2 pp720-721,10.1136/annrheumdis-2016-eular.2054,,,,Missing EZProxy credentials.,unreachable,,na
9740088,"PER-041-15. A PHASE 3B, RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT SC IN COMBINATION WITH METHOTREXATE COMPARED TO METHOTREXATE MONOTHERAPY IN ACHIEVING CLINICAL REMISSION IN ADULTS WITH EARLY RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE NAIVE. http://www.who.int/trialsearch/Trial2.aspx?TrialID=PER-041-15. (2016)   pp",10.3410/f.14174.471676,,,,Missing EZProxy credentials.,unreachable,,na
9741038,NCT01142726. Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis. https://clinicaltrials.gov/show/NCT01142726. (2010)   pp,10.1186/isrctn49682259,,,,Missing EZProxy credentials.,unreachable,,na
9737594,"Keystone Edward C; Ahmad Harris A; Yazici Yusuf; Bergman Martin J. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford, England). (2019)   pp",10.1093/rheumatology/kez455,http://academic.oup.com/rheumatology/article-pdf/59/8/2090/33532505/kez455.pdf,http://academic.oup.com/rheumatology/article-pdf/59/8/2090/33532505/kez455.pdf,,,pdf,,PDF
9742406,"Keystone EC; Ahmad HA; Yazici Y; Bergman MJ. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford, England). (2019)   pp",10.1093/rheumatology/kez455,http://academic.oup.com/rheumatology/article-pdf/59/8/2090/33532505/kez455.pdf,http://academic.oup.com/rheumatology/article-pdf/59/8/2090/33532505/kez455.pdf,,,pdf,,PDF
11084953,"Keystone Edward C; Ahmad Harris A; Yazici Yusuf; Bergman Martin J. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford, England). (2020) 59 8 pp2090-2098",10.1093/rheumatology/kez455,http://academic.oup.com/rheumatology/article-pdf/59/8/2090/33532505/kez455.pdf,http://academic.oup.com/rheumatology/article-pdf/59/8/2090/33532505/kez455.pdf,,,pdf,,PDF
9742882,EUCTR2015-001275-50-SE. Effects of abatacept in patients who have recently been diagnosed with rheumatoid arthritis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-001275-50-SE. (2015)   pp,10.1186/isrctn89222125,,,,Missing EZProxy credentials.,unreachable,,na
11085777,"Wu C; Hu Y; Schafer P; Connolly SE; Wong R; Nielsen SH; Bay-Jensen AC; Emery P; Tanaka Y; Bykerk VP; Bingham CO; Huizinga TW; Fleischmann R; Liu J. Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open. (2022) 8 2 pp",10.1136/rmdopen-2022-002683,,https://rmdopen.bmj.com/rmdopen/8/2/e002683.full.pdf,,,pdf,,Page Not Found
11084612,. Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH). . (2021)   pp,10.1007/s15002-021-3390-4,https://link.springer.com/article/10.1007/s15002-021-3390-4/fulltext.html,https://link.springer.com/article/10.1007/s15002-021-3390-4/fulltext.html,,,html,,Article
9736855,Baek Han Joo; Lim Mie Jin; Park Won; Park Sung Hwan; Shim Seung-Cheol; Yoo Dae-Hyun; Kim Hyun Ah; Lee Soo Kon; Lee Yun Jong; Park Young Eun; Cha Hoon-Suk; Song Yeong-Wook. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. The Korean journal of internal medicine. (2019) 34 4 pp917-931,10.1111/pai.13772/v2/response1,,,,Missing EZProxy credentials.,unreachable,,na
9262152,"Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis and rheumatology. (2016) 68 12 pp2867-2877",10.1002/art.39801,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.39801,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.39801,,,html,,Page Not Found
9740031,EUCTR2013-003984-72-ES. A Study Investigating the Efficacy and Safety of ABT-494 given with Methotrexate in Subjects with Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-003984-72-ES. (2014)   pp,10.1080/14656566.2017.1370453,,,,Missing EZProxy credentials.,unreachable,,na
9256843,"Strand V; Tundia N; Friedman A. Patient-reported outcomes of long-term upadacitinib use in patients with rheumatoid arthritis: interim analysis results of a phase 2, open-label extension study. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2017. United states. (2017) 69 Supplement 10) (no pagination pp",10.1002/art.40321,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.40321,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.40321,,,html,,Page Not Found
9262517,"Nurmohamed M; Zhang Y; Lin J; Camp H. Changes in c-reactive protein and lipid levels in patients with rheumatoid arthritis treated with ABT-494 a selective JAK-1 inhibitor. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp280",10.1136/annrheumdis-2017-eular.2807,,,,Missing EZProxy credentials.,unreachable,,na
9262555,"Genovese MC; Kremer J; Zhong S; Friedman A. Long-term safetyand efficacyof upadacitinib (ABT-494), an oral JAK-1 inhibitor in patients with rheumatoid arthritis in an open-label extension study. Journal of clinical rheumatology. (2018) 24 (3 Supplement 1) 3 Supplement 1 ppS85",10.1136/annrheumdis-2018-eular.7021,,,,Missing EZProxy credentials.,unreachable,,na
9737754,"Nurmohamed M; Zhang Y; Lin JH; Camp HS. Changes in C-reactive protein and lipid levels in patients with rheumatoid arthritis treated with upadacitinib (ABT-494), a selective JAK-1 inhibitor. International journal of rheumatic diseases. (2017) Conference: 19th Asia Pacific League of Associations for Rheumatology Congress, APLAR 2017. . 20 Supplement 1 pp100",10.1136/annrheumdis-2017-eular.2807,,,,Missing EZProxy credentials.,unreachable,,na
9738557,"Strand V; Genovese M; Kremer J; Schiff M; Li Y; Sokolove J. Changes in hemoglobin levels upon treatment with ABT-494, a selective JAK-1 inhibitor, and relation to baseline levels of c-reactive protein. Annals of the rheumatic diseases. (2017) Conference: Annual European Congress of Rheumatology, EULAR 2017. Spain. 76 Supplement 2 pp283",10.1136/annrheumdis-2017-eular.3216,,,,Missing EZProxy credentials.,unreachable,,na
9742801,"EUCTR2013-003530-33-BG. Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) with ABT-494. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013-003530-33-BG. (2014)   pp",10.1186/isrctn87762302,,,,Missing EZProxy credentials.,unreachable,,na
9257651,Bao J; Yue T; Li T; He DY; Bao YX. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist. International journal of rheumatic diseases. (2016) 19 4 pp370-376,10.1111/1756-185x.12387,,,,Missing EZProxy credentials.,unreachable,,na
9257809,"Buvanendran A; Barkin R. Lumiracoxib. Drugs of today (Barcelona, Spain : 1998). (2007) 43  3 pp137-147",10.1358/dot.2007.43.3.1062673,,,,Missing EZProxy credentials.,unreachable,,na
9736731,ISRCTN62900439. Leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha (TNF-alpha) blocking agents in rheumatoid arthritis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN62900439. (2010)   pp,10.1186/isrctn62900439,,,,Missing EZProxy credentials.,unreachable,,na
9256777,van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis and rheumatism. (2009) 61 1 pp4-12,10.1002/art.24367,,,,Missing EZProxy credentials.,unreachable,,na
9257496,Markusse IM; Akdemir G; Dirven L; Goekoop-Ruiterman YP; van Groenendael JH; Han KH; Molenaar TH; Le Cessie S; Lems WF; van der Lubbe PA; Kerstens PJ; Peeters AJ; Ronday HK; de Sonnaville PB; Speyer I; Stijnen T; Ten Wolde S; Huizinga TW; Allaart CF. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Annals of internal medicine. (2016) 164 8 pp523-531,10.7326/m15-0919,https://www.acpjournals.org/doi/pdf/10.7326/M15-0919,https://www.acpjournals.org/doi/pdf/10.7326/M15-0919,,,html,,Article
9257938,Van Den Broek M; Dirven L; Kroon H; Westedt M; Gerards A; Kerstens P; Huizinga T; Lems W; Allaart C. Large joint damage after 8 years of das-steered treatment in early rheumatoid arthritis (RA) patients. Annals of the Rheumatic Disease. (2013) 71  pp,10.1136/annrheumdis-2012-eular.2540,,,,Missing EZProxy credentials.,unreachable,,na
9258306,Klarenbeek NB; van der Kooij SM; Huizinga TJ; Goekoop-Ruiterman YP; Hulsmans HM; van Krugten MV; Speyer I; de Vries-Bouwstra JK; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Annals of the rheumatic diseases. (2010) 69 7 pp1342-1345,10.1136/ard.2009.124180,,,,Missing EZProxy credentials.,unreachable,,na
9260266,van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; van Zeben D; Kerstens PJ; Gerards AH; van Groenendael JH; Hazes JM; Breedveld FC; Allaart CF; Dijkmans BA. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Annals of the rheumatic diseases. (2007) 66 10 pp1356-1362,10.1136/ard.2006.066662,,,,Missing EZProxy credentials.,unreachable,,na
9260324,"de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis and rheumatism. (2008) 58 5 pp1293-1298",10.1002/art.23439,,,,Missing EZProxy credentials.,unreachable,,na
9260650,"Klarenbeek NB; G‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚Äö√Ñ‚Ä†‚Äö√†√∂‚Äö√†√á¬¨¬®¬¨¬Æ‚Äö√Ñ√∂‚àö‚Ä†¬¨¬•ler-Y‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚Äö√Ñ‚Ä†‚Äö√†√∂‚Äö√†√á¬¨¬®¬¨¬Æ‚Äö√Ñ√∂‚àö‚Ä†¬¨¬•ksel M; van der Kooij SM; Han KH; Ronday HK; Kerstens PJ; Seys PE; Huizinga TW; Dijkmans BA; Allaart CF. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Annals of the rheumatic diseases. (2011) 70 6 pp1039-1046",10.1136/ard.2010.141234,,,,Missing EZProxy credentials.,unreachable,,na
9260945,Allaart CF; Lems WF; Huizinga TW. The BeSt way of withdrawing biologic agents. Clinical and experimental rheumatology. (2013) 31 4 Suppl 78 ppS14-8,10.1093/rheumatology/kes362,http://academic.oup.com/rheumatology/article-pdf/52/7/1202/17387911/kes362.pdf,http://academic.oup.com/rheumatology/article-pdf/52/7/1202/17387911/kes362.pdf,,,pdf,,PDF
9261492,Markusse IM; Akdemir G; Van Den Broek M; Dirven L; Goekoop RJ; Han KH; Van Oosterhout M; Kerstens PJSM; Lems WF; Huizinga TWJ; Allaart CF. 10 years of treat-to-target therapy in rheumatoid arthritis patients (the best study): Clinical and radiological outcomes. Arthritis and rheumatism. (2013) 65  ppS620,10.1136/annrheumdis-2014-eular.2015,,,,Missing EZProxy credentials.,unreachable,,na
9262013,Markusse I; Dirven L; Han H; Ronday K; Speyer I; Kerstens P; Lems W; Huizinga T; Allaart C. Survival in early rheumatoid arthritis patients after 10 years of targeted treatment. Annals of the rheumatic diseases. (2015) 74  pp84-85,10.1136/annrheumdis-2015-eular.1638,,,,Missing EZProxy credentials.,unreachable,,na
9262435,"Loef M; Kroon FP; Bergstra SA; Van Der Pol JA; Lems WF; Kerstens PJ; Allaart CF; Kloppenburg M. Prolonged TNF-inhibitor treatment duration is associated with lower risk of hand osteoarthritis progression in patients with recent-onset rheumatoid arthritis after 10-year follow-up. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp976",10.1136/annrheumdis-2017-eular.2337,,,,Missing EZProxy credentials.,unreachable,,na
9263188,Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Allaart CF; van Zeben D; Kerstens PJ; Hazes JM; Zwinderman AH; Peeters AJ; de Jonge-Bok JM; Mall‚Äö√†√∂¬¨¬©e C; de Beus WM; de Sonnaville PB; Ewals JA; Breedveld FC; Dijkmans BA. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Annals of internal medicine. (2007) 146 6 pp406-415,10.7326/0003-4819-146-6-200703200-00005,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-146-6-200703200-00005,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-146-6-200703200-00005,,,html,,Article
9263250,van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis and rheumatism. (2009) 61 3 pp291-299,10.1002/art.24169,,,,Missing EZProxy credentials.,unreachable,,na
9263264,van der Bijl AE; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Ten Wolde S; Han KH; van Krugten MV; Allaart CF; Breedveld FC; Dijkmans BA. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis and rheumatism. (2007) 56 7 pp2129-2134,10.1002/art.22718,,,,Missing EZProxy credentials.,unreachable,,na
9263323,van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Annals of the rheumatic diseases. (2012) 71 2 pp245-248,10.1136/annrheumdis-2011-200379,,,,Missing EZProxy credentials.,unreachable,,na
9263413,Dirven L; Visser K; Klarenbeek NB; Ewals JAPM; Han KH; Peeters AJ; Kerstens PJSM; Huizinga TWJ; Dijkmans BAC; Allaart CF. Towards personalized treatment: Predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. Scandinavian journal of rheumatology. (2012) 41  1 pp15-19,10.3109/03009742.2011.594964,,,,Missing EZProxy credentials.,unreachable,,na
9263429,Koevoets R; Dirven L; Klarenbeek NB; van Krugten MV; Ronday HK; van der Heijde DM; Huizinga TW; Kerstens PS; Lems WF; Allaart CF. 'Insights in the relationship of joint space narrowing versus erosive joint damage and physical functioning of patients with RA'. Annals of the rheumatic diseases. (2013) 72 6 pp870-874,10.1136/annrheumdis-2011-201191,,,,Missing EZProxy credentials.,unreachable,,na
9263626,"Loef M; Kroon FP; Bergstra SA; Van Der Pol JA; Lems WF; Kerstens PJ; Allaart CF; Kloppenburg M. Tumor necrosis factor-inhibitor treatment duration is associated with lower risk of hand osteoarthritis progression in patients with recent-onset rheumatoid arthritis after 10-year follow-up. Osteoarthritis and cartilage. (2018) Conference: 2018 Osteoarthritis Research Society International, OARSI World Congress. United Kingdom. 26 Supplement 1 ppS300-S301",10.1016/j.joca.2018.02.604,,,,Missing EZProxy credentials.,unreachable,,na
9739099,Koevoets R; Klarenbeek N B; Van Der Heijde; D M F M; Van Krugten; M V; Van Schaardenburg; Dijkmans B; Huizinga T W J. Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis and rheumatism. (2009) 60 SUPPL. 10 pp957,10.1002/art.24661,,,,Missing EZProxy credentials.,unreachable,,na
9739444,Koevoets R; Klarenbeek NB; Van Der Heijde DMFM; Van Krugten MV; Van Schaardenburg D; Dijkmans B; Huizinga TWJ. Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores. Arthritis and rheumatism. (2009) 60  pp957-,10.1002/art.24661,,,,Missing EZProxy credentials.,unreachable,,na
9740040,ISRCTN32675862. Treatment strategies for Rheumatoid Arthritis (BeSt - BehandelStrategie‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚Äö√Ñ‚Ä†‚Äö√†√∂‚Äö√†√á¬¨¬®¬¨¬Æ¬¨¬®‚Äö√Ñ¬¢n in Reumato‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚Äö√Ñ‚Ä†‚Äö√†√∂‚Äö√†√á‚Äö√Ñ√∂‚àö‚Ä†‚àö‚àÇ‚Äö√†√∂‚Äö√¢¬ßde Artritis). http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN32675862. (2005)   pp,10.4324/9780203187838.bmatt3,,,,[Errno 11001] getaddrinfo failed,unreachable,,na
11087242,Van Der Pol J; Bergstra SA; Huizinga T; Allaart C. PREDNISONE USE and the INCIDENCE of HYPERGLYCEMIA or DIABETES in PATIENTS with RHEUMATOID ARTHRITIS; A 10-YEAR SUB ANALYSIS of the BEST STUDY. Annals of the rheumatic diseases. (2022) 81 Supplement 1 pp181,10.1136/annrheumdis-2022-eular.4474,,,,Missing EZProxy credentials.,unreachable,,na
9743074,Bergstra Sytske Anne; Van Der Pol Joy A; Riyazi Naghmeh; Goekoop-Ruiterman Yvonne P M; Kerstens Pit J S M; Lems Willem; Huizinga Tom W J; Allaart Cornelia F. Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?. RMD open. (2020) 6 1 pp,10.1136/rmdopen-2020-001242,,https://rmdopen.bmj.com/rmdopen/6/1/e001242.full.pdf,,,pdf,,Page Not Found
9737262,UMIN000030760. A pilot study of a simple navigation system for artificial hip joint surgery using augmented reality technology. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000030760. (2018)   pp,10.1016/j.jjoisr.2024.06.002,,,,Missing EZProxy credentials.,unreachable,,na
9740192,"EUCTR2015-000581-58-CZ. A Randomized,Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2015-000581-58-CZ. (2015)   pp",10.1186/isrctn43336433,,,,Missing EZProxy credentials.,unreachable,,na
11083927,"Studenic P; Bond G; Kerschbaumer A; Becede M; Pavelka K; Karateev D; Stieger J; Puchner R; Mueller RB; Puchhammer-Stockl E; Durechova M; Loiskandl M; Perkmann T; Olejarova M; Luchikhina E; Steiner C-W; Bonelli M; Smolen JS; Aletaha D. Torque Teno Virus Quantification for Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis. Rheumatology (Oxford, England). (2021) 61 7 pp2815-2825",10.1093/rheumatology/keab839,https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keab839/42378011/keab839.pdf,https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keab839/42378011/keab839.pdf,,,pdf,,PDF
9257681,"Nasonov E; Mazurov V; Plaksina T; Nesmeyanova O; Knyazeva L; Eremeeva A; Chernyaeva E; Ivanov R. Interchangeability of innovator rituximab and its biosimilar: results from international controlled comparative 1-year study in patients with active rheumatoid arthritis. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp2046-2047",10.1002/art.39977,,,,Missing EZProxy credentials.,unreachable,,na
9742604,"Eremeeva A; Chernyaeva E; Ivanov R; Nasonov E; Knyazeva L. Comparison of efficacy and safety of rituximab biosimilar, BCD-020, and innovator rituximab in patients with active rheumatoid arthritis refractory to TNFa inhibitors. Annals of the rheumatic diseases. (2016) 75 Supplement 2 pp513-514",10.1136/annrheumdis-2016-eular.1715,,,,Missing EZProxy credentials.,unreachable,,na
9261496,Kivitz A; Olech E; Borofsky MA; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Wells C; Wimalasundera S; Douglass W; Pope JE. The safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDS in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA). Arthritis and rheumatism. (2013) 65 var.pagings ppS604-S605,10.1002/acr.22384,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.22384,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.22384,,,html,,PDF
9737343,"EUCTR2010-019912-18-ES. A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis. Estudio randomizado, doble ciego, con grupos de tratamiento paralelos, para evaluar la seguridad y el efecto sobre el resultado cl‚àö‚â†nico de tocilizumab SC frente a placebo SC en combinaci‚àö‚â•n con f‚àö¬∞rmacos antirreum‚àö¬∞ticos modificadores de la enfermedad (FAMEs) tradicionales, en pacientes con artritis reumatoide activa moderada a severa. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2010-019912-18-ES. (2011)   pp",10.1016/j.acuro.2024.05.005,,,,Missing EZProxy credentials.,unreachable,,na
9262262,"Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. Journal of clinical pharmacology. (2017) 57 4 pp459-468",10.1002/jcph.826,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcph.826,https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fjcph.826,,,html,,Page Not Found
9738583,"Harrison M; Boonen A; Tugwell P; Symmons D. Same question, different answer: a comparison of global health assessments using vas scales. Rheumatology.. (2009) 48  ppi110",10.1007/s11136-009-9546-3,http://link.springer.com/article/10.1007/s11136-009-9546-3/fulltext.html,http://www.shef.ac.uk/content/1/c6/01/87/47/04_6FT.pdf,,,pdf,,Page Not Found
9257165,Kameda H; Kurasawa T; Nagasawa H; Amano K; Takeuchi T. The addition of another disease-modifying anti-rheumatic drug to methotrexate in place of infliximab reduces the flare rate during 2 years after infliximab discontinuation in patients with rheumatoid arthritis. Arthritis and rheumatism. (2012) 64  ppS206,10.3109/14397595.2013.844886,,,,Missing EZProxy credentials.,unreachable,,na
9258391,"Glintborg B; Sorensen IJ; Jensen DV; Krogh NS; Loft AG; Espesen J; Olsen J; Hendricks O; Grydehoj J; Hansen IMJ; Sorensen MV; Chrysidis S; Andersen BL; Manilo N; Klarlund M; Andersen LS; Nordin H; Kristensen S; Norregaard J; Hetland ML. A nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Eleven months' clinical outcomes from the Danbio registry. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp1255-1258",10.1136/annrheumdis-2016-eular.1785,,,,Missing EZProxy credentials.,unreachable,,na
9258402,"Bykerk VP; Emery P; Weinblatt M; Burmester G-R; Furst DE; Mariette X; Van Vollenhoven R; Purcaru O; Ralston P; Bingham C. Cinical responses and improvements in patient-reported outcomes are associated with increased productivity in the workplace and at home in rheumatoid arthritis patients treated with certolizumab pegol. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp775-776",10.1016/j.jval.2016.09.1150,,,,Missing EZProxy credentials.,unreachable,,na
9261831,"Weinblatt M; Bingham C; Burmester G; Bykerk VP; Furst DE; Mariette X; Van Der Heijde D; Tatla D; Arendt C; Mountian I; Van Lunen B; Emery P. Certolizumab pegol in combination with methotrexate in dmard-naive patients with active, severe, progressive rheumatoid arthritis: results from a randomized, double-blind, controlled phase 3 study. Arthritis and rheumatology. (2015) 67 no pagination pp",10.1136/annrheumdis-2015-eular.1493,,,,Missing EZProxy credentials.,unreachable,,na
9261866,"Emery P; Bingham CO; Burmester G-R; Bykerk VP; Furst DE; Mariette X; Van Der Heijde D; Tatla D; Arendt C; Mountian I; Van Lunen B; Weinblatt M. The first study of certolizumab pegol in combination with methotrexate in dmard-naive early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the c-early randomized, double-blind, controlled phase 3 study. Annals of the rheumatic diseases. (2015) 74  pp712",10.1136/annrheumdis-2015-eular.1493,,,,Missing EZProxy credentials.,unreachable,,na
9261923,"Emery P; Bingham C; Burmester G; Bykerk V; Furst D; Mariette X; Purcaru O; Coteur G; Vanlunen B; Weinblatt M. Improvements in patient-reported outcomes following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in dmard-naive patients with severe, active and progressive rheumatoid arthritis: results from the c-early randomized, double-blind, controlled phase 3 study. Value in health. (2015) 18 7 ppA707-A708",10.1016/j.jval.2015.09.2660,,,,Missing EZProxy credentials.,unreachable,,na
9262077,Bykerk VP; Emery P; Weinblatt ME; Burmester G; Furst DE; Mariette X; Van Vollenhoven R; Ralston P; Purcaru O; Bingham C. Clinical responses and improvements in patient-reported outcomes are associated with increased productivity in the workplace and at home in rheumatoid arthritis patients treated with certolizumab pegol. Value in health. Conference: ISPOR 19th annual european congress. Austria. Conference start: 20161029. Conference end: 20161102. (2016) 19 7 ppA545,10.1016/j.jval.2016.09.1150,,,,Missing EZProxy credentials.,unreachable,,na
9740280,"EUCTR2011-001729-25-GB. Study designed to demonstrate the efficacy and safety of Certolizumab pegol in combination with Methotrexate in the treatment of subjects suffering from early, progressive active rheumatoid arthritis. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-001729-25-GB. (2012)   pp",10.1007/s00393-016-0133-z,http://link.springer.com/article/10.1007/s00393-016-0133-z/fulltext.html,http://link.springer.com/article/10.1007/s00393-016-0133-z/fulltext.html,,,html,,Article
9741121,"NCT01521923. A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na√Øve Adults With Early Active Rheumatoid Arthritis. https://clinicaltrials.gov/show/NCT01521923. (2012)   pp",10.1016/j.clinthera.2009.08.014,,,,Missing EZProxy credentials.,unreachable,,na
9258378,"Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Ralston P; Van Der Heijde D; Miyasaka N; Koike T. Maintenance of clinical remission and radiographic non-progression with mtx after completion of 1 year initial treatment with certolizumab pegol in Japanese patients with early rheumatoid arthritis. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp4315-4317",10.3109/14397595.2014.904475,,,,Missing EZProxy credentials.,unreachable,,na
9261864,"Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Togo O; Okada T; Van Der Heijde D; Miyasaka N; Koike T. Baseline parameters identified in early, methotrexate-naive rheumatoid arthritis patients with better outcomes with certolizumab pegol+methotrexate compared to placebo+methotrexate: post-hoc analyses of c-opera, a randomized, controlled, phase 3 study. Annals of the Rheumatic Diseases.Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2015 Rome Italy.Conference Start: 20150610 Conference End: 20150613.Conference Publication: (var.pagings). (2015) 74  pp716-717",10.1136/annrheumdis-2015-eular.1501,,,,Missing EZProxy credentials.,unreachable,,na
9261584,Burmester GR; Kivitz AJ; Kupper H; Arulmani U; Florentinus S; Goss SL; Rathmann SS; Fleischmann RM. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the rheumatic diseases. (2015) 74 6 pp1037-1044,10.1136/annrheumdis-2013-204769,,,,Missing EZProxy credentials.,unreachable,,na
9737980,"Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Togo O; Okada T; Van Der Heijde; D M; Miyasaka N; Koike T. The first, multicenter, double-blind, randomized, parallel-group study of certolizumab pegol in early rheumatoid arthritis demonstrates inhibition of joint damage progression. Arthritis and rheumatology. (2014) 66 SUPPL. 10 ppS1078-S1079",10.1136/annrheumdis-2014-eular.1448,,,,Missing EZProxy credentials.,unreachable,,na
9741317,Tanaka Yoshiya; Atsumi Tatsuya; Yamamoto Kazuhiko; Takeuchi Tsutomu; Yamanaka Hisashi; Ishiguro Naoki; Eguchi Katsumi; Watanabe Akira; Origasa Hideki; Shoji Toshiharu; Miyasaka Nobuyuki; Koike Takao. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. International journal of rheumatic diseases. (2020) 23 3 pp316-324,10.1111/1756-185x.13780,https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.13780,https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.13780,,,html,,PDF
11088227,Tanaka Yoshiya; Atsumi Tatsuya; Yamamoto Kazuhiko; Takeuchi Tsutomu; Yamanaka Hisashi; Ishiguro Naoki; Eguchi Katsumi; Watanabe Akira; Origasa Hideki; Shoji Toshiharu; Miyasaka Nobuyuki; Koike Takao. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. International journal of rheumatic diseases. (2020) 23 3 pp316-324,10.1111/1756-185x.13780,https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.13780,https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.13780,,,html,,PDF
9261282,Haraoui B; Thorne C; Keystone E; Poulin-Costello M; Trottier E; Vieira A; Pope J. Clinical and radiographic outcomes in patients with rheumatoid arthritis treated with etanercept or etanercept + methotrexate: Two-year results from the canadian methotrexate and etanercept outcome study (CAMEO). Journal of rheumatology. (2014) 41  7 pp1506-1507,10.1136/annrheumdis-2014-eular.1054,,,,Missing EZProxy credentials.,unreachable,,na
9261491,Haraoui B; Thorne JC; Keystone EC; Poulin-Costello M; Trottier E; Vieira A; Pope JE. Clinical and radiographic outcomes with etanercept and etanercept and methotrexate in patients with rheumatoid arthritis: Two-year results from the Canadian methotrexate and etanercept outcome study (CAMEO). Arthritis and rheumatism. (2013) 65  ppS622,10.1093/rheumatology/kev338,http://academic.oup.com/rheumatology/article-pdf/55/2/327/5159107/kev338.pdf,http://academic.oup.com/rheumatology/article-pdf/55/2/327/5159107/kev338.pdf,,,pdf,,PDF
9261809,Pope JE; Keystone EC; Thorne JC; Poulin-Costello M; Phan-Chronis K; Haraoui B. Study completion and etanercept retention in patients with rheumatoid arthritis treated with etanercept monotherapy versus etanercept and methotrexate combination therapy. Arthritis and rheumatology. (2015) 67 no pagination pp,10.1136/annrheumdis-2014-eular.1054,,,,Missing EZProxy credentials.,unreachable,,na
9736948,Pope J; Keystone E; Haraoui B; Thorne J C; Poulin-Costello M. Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian methotrexate and etanercept outcome study: a randomized trial of etanercept and methotrexate vs etanercept alone in rheumatoid arthritis. Arthritis and rheumatism. (2011) 63 10 SUPPL. 1 pp,10.1136/annrheumdis-2012-eular.389,,,,Missing EZProxy credentials.,unreachable,,na
9738955,Pope J E; Keystone E; Haraoui B; Thorne C; Poulin-Costello M. Number of cardiovascular risk factors may be associated with higher disease activity severity. Exploratory analysis of baseline data from the canadian MTX and etanercept outcome study: a randomized trial of etanercept and MTX vs etanercept alone in RA. Annals of the rheumatic disease. (2013) 71 SUPPL. 3 pp,10.1136/annrheumdis-2012-eular.389,,,,Missing EZProxy credentials.,unreachable,,na
9741329,Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. Rheumatology. (2016) 55 2 pp327-334,10.1093/rheumatology/kev338,http://academic.oup.com/rheumatology/article-pdf/55/2/327/5159107/kev338.pdf,http://academic.oup.com/rheumatology/article-pdf/55/2/327/5159107/kev338.pdf,,,pdf,,PDF
9260613,Bakker MF; Jacobs JW; Welsing PM; van der Werf JH; Linn-Rasker SP; van der Veen MJ; Lafeber FP; Bijlsma JW; Utrecht Arthritis Cohort Study Group. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Annals of the rheumatic diseases. (2010) 69 10 pp1849-1852,10.1136/ard.2009.124065,,,,Missing EZProxy credentials.,unreachable,,na
9261969,Nair SC; Welsing PM; Jacobs JW; van Laar JM; Rensen WH; Ardine de Wit G; Bijlsma JW; Lafeber FP. Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for monitoring joint inflammation in early rheumatoid arthritis. Clinical and experimental rheumatology. (2015) 33 6 pp831-838,10.1136/annrheumdis-2014-eular.2890,,,,Missing EZProxy credentials.,unreachable,,na
9261222,Bakker MF; Jacobs JWG; Welsing PMJ; Verstappen SMM; Tekstra J; Ton E; Geurts MAW. Double-blind randomized CAMERA-II trial: Better control of disease and erosive joint damage with inclusion of low-dose prednisone into a MTX-based tight control strategy for early rheumatoid arthritis. Arthritis and rheumatism. (2011) 63 10 SUPPL. 1 pp,10.7326/0003-4819-156-5-201203060-00004,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-156-5-201203060-00004,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-156-5-201203060-00004,,,html,,Article
9258294,"Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW; Utrecht Rheumatoid Arthritis Cohort Study Group. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Annals of internal medicine. (2012) 156 5 pp329-339",10.7326/0003-4819-156-5-201203060-00004,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-156-5-201203060-00004,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-156-5-201203060-00004,,,html,,Article
9261405,Van Der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; Welsing PM; Bijlsma JW. No decrease in bone mineral density when prednisone is added to a methotrexate-based tight control strategy for early rheumatoid arthritis. Annals of the Rheumatic Disease. (2013) 71  pp,10.1136/annrheumdis-2012-eular.405,,,,Missing EZProxy credentials.,unreachable,,na
9262684,"Safy M; De Hair M; Welsing P; Van Laar J; Jacobs J. Smoking is negatively associated with clinical response to concomitant prednisone use in early rheumatoid arthritis. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2018. Netherlands. (2018) 77 Supplement 2 pp281-282",10.1136/annrheumdis-2018-eular.6494,,,,Missing EZProxy credentials.,unreachable,,na
9262949,Porter DR; McInnes I; Hunter J; Capell HA. Outcome of second line therapy in rheumatoid arthritis. Annals of the rheumatic diseases. (1994) 53 12 pp812-815,10.1136/ard.53.12.812,,,,Missing EZProxy credentials.,unreachable,,na
9261472,Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A. Switching from immediate release (IR) prednisone to delayed release (DR) prednisone improves patient reported outcomes in rheumatoid arthritis (RA) patients on conventional disease-modifying antirheumatic drugs (DMARDS). Arthritis and rheumatism. (2013) 65  ppS963-S964,10.1136/annrheumdis-2014-eular.1467,,,,Missing EZProxy credentials.,unreachable,,na
9738855,"Dejaco C; Duftner C. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Journal fur mineralstoffwechsel. (2008) 15 2 pp101",10.3410/f.1099142.555355,,,,Missing EZProxy credentials.,unreachable,,na
9742538,Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten R E; Supronik J; Szombati I; Romer U; Witte S; Witte K G. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Annals of the rheumatic diseases. (2012)   pp,10.1136/annrheumdis-2011-201067,,,,Missing EZProxy credentials.,unreachable,,na
9739596,"UMIN000004412. Corticosteroid-sparing effect of Actemra in patients with Rheumatoid Arthritis refractory to anti-TNF agents, methotrexate and corticosteroid. http://www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000004412. (2010)   pp",10.1186/isrctn62900439,,,,Missing EZProxy credentials.,unreachable,,na
9257468,Scott IC; Walker J; Quist J; Spain S; Tan R; Okada Y; Raychaudhuri S; Steer S; Cope AP; Lewis CM. Genetic susceptibility variants for rheumatoid arthritis do not associate with radiological progression in early active disease. Rheumatology (United Kingdom). (2014) 53  ppi158,10.1093/rheumatology/keu122.002,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i158/9578854/keu122.002.pdf,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i158/9578854/keu122.002.pdf,,,pdf,,Article
9257018,"Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Annals of the rheumatic diseases. (2017) 76 7 pp1279-1284",10.1136/annrheumdis-2016-210561,,,,Missing EZProxy credentials.,unreachable,,na
9737322,Ma M H Y; Dahanayake C; Scott I C; Kingsley G H; Cope A P; Scott D L. Serological status: a predictor of response to intensive therapy in rheumatoid arthritis. Lancet. (2013) 381 SUPPL. 1 ppS67,10.1016/s0140-6736(13)60508-5,,,,Missing EZProxy credentials.,unreachable,,na
9737727,Seegobin SD; Ma MHY; Dahanayake C; Cope AP; Scott DL; Lewis CM; Scott IC. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids. Rheumatology (united kingdom). (2014) 53  ppi92-i93,10.1093/rheumatology/keu101.017,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i92/9578475/keu101.017.pdf,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i92/9578475/keu101.017.pdf,,,pdf,,Article
9738525,Wailoo A; Alava MH; Scott IC; Ibrahim F; Scott DL. Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology (united kingdom). (2014) 53 10 pp1773-1777,10.1093/rheumatology/keu039,http://academic.oup.com/rheumatology/article-pdf/53/10/1773/17388298/keu039.pdf,http://academic.oup.com/rheumatology/article-pdf/53/10/1773/17388298/keu039.pdf,,,pdf,,Article
9739128,Seegobin S D; Ma M H Y; Dahanayake C; Cope A P; Scott D L; Lewis C M; Scott I C. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids. Rheumatology (united kingdom). (2014) 53 SUPPL. 1 pp,10.1093/rheumatology/keu101.017,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i92/9578475/keu101.017.pdf,http://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i92/9578475/keu101.017.pdf,,,pdf,,Article
9263546,Scott IC; Ibrahim F; Scott DL; Lewis CM. The impact of intensive treatment and remission on health-related quality of life in rheumatoid arthritis. The lancet. Conference: spring meeting for clinician scientists in training 2016. London united kingdom. Conference start: 20160225. Conference end: 20160225. Conference publication: (var.pagings). (2016) 387  pp90,10.1016/s0140-6736(16)00477-3,,,,Missing EZProxy credentials.,unreachable,,na
9257640,"Decock D; Westhovens R; Stouten V; Van Der Elst K; Joly J; Verschueren P. Patient characteristics predicting remission using intensive treatment strategies in early rheumatoid arthritis. Arthritis and rheumatology. Conference: american college of rheumatology/association of rheumatology health professionals annual scientific meeting, ACR/ARHP 2016. United states. Conference start: 20161111. Conference end: 20161116. (2016) 68  pp3377-3378",10.1002/art.39977,,,,Missing EZProxy credentials.,unreachable,,na
9259249,Clark P; Casas E; Tugwell P; Medina C; Gheno C; Tenorio G; Orozco JA. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Annals of internal medicine. (1993) 119 11 pp1067-1071,10.7326/0003-4819-119-11-199312010-00002,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-119-11-199312010-00002,https://www.acpjournals.org/doi/pdf/10.7326/0003-4819-119-11-199312010-00002,,,html,,Article
9261559,De Cock D; Westhovens R; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van Der Elst K; Verschueren P. Comparison of MTX therapy with or without a moderate dose glucocorticoid bridging scheme in early rheumatoid arthritis patients lacking classical poor prognostic markers: Week 16 results from the randomized multicenter carera trial. Annals of the rheumatic diseases. (2014) 73  pp,10.1136/annrheumdis-2014-eular.2144,,,,Missing EZProxy credentials.,unreachable,,na
9262429,"Pazmino S; Westhovens R; Stouten V; Joly J; Van Der Elst K; Verschueren P. Long term use of analgesics and NSAIDS in early RA: lessons from the carera study. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2017. Spain. (2017) 76 Supplement 2 pp765-766",10.1136/annrheumdis-2017-eular.3399,,,,Missing EZProxy credentials.,unreachable,,na
9262650,"Stouten V; Michiels S; Belba A; Westhovens R; Verschueren P. Effectiveness of a randomized step-down to methotrexate or leflunomide maintenance therapy in patients with low disease activity, 40 weeks after starting combined methotrexate-leflunomide remission induction therapy in early rheumatoid arthritis: results from the carera trial. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2018. Netherlands. (2018) 77 Supplement 2 pp967-968",10.1136/annrheumdis-2018-eular.3036,,,,Missing EZProxy credentials.,unreachable,,na
9262725,"Stouten V; Joly J; Pazmino S; Van Der Elst K; DeCock D; Westhovens R; Verschueren P. Long-term effectiveness of the cobra slim remission induction and treat to target strategy in patients with early rheumatoid arthritis lacking classical markers of poor prognosis: 2 year results of the carera trial. Annals of the rheumatic diseases. Conference: annual european congress of rheumatology, EULAR 2018. Netherlands. (2018) 77 Supplement 2 pp67",10.1136/annrheumdis-2018-eular.2535,,,,Missing EZProxy credentials.,unreachable,,na
9263571,"Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van Der Elst K; Westhovens R. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Annals of the rheumatic diseases. (2017) 76 3 pp511-520",10.1136/annrheumdis-2016-209212,,,,Missing EZProxy credentials.,unreachable,,na
9737469,"Verschueren P; De Cock; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen; Van Essche; Sileghem A; De Brabanter; Joly J; Meyfroidt S; Van Der Elst; Westhovens R. Associated with a glucocorticoid bridging scheme, methotrexate is as effective alone as in combination with other DMARDs for early rheumatoid arthritis, with fewer reported side effects: 16 weeks remission induction data from the carera trial. Annals of the rheumatic diseases. (2014) 73 SUPPL. 2 pp",10.1136/annrheumdis-2014-eular.2137,,,,Missing EZProxy credentials.,unreachable,,na
9738396,De Cock; Westhovens R; Stouten V; Van Der Elst; Joly J; Verschueren P. Does BMI increase in patients with early rheumatoid arthritis when treated with short-term glucocorticoid remission induction schemes?. Annals of the rheumatic diseases. (2016) 75 Supplement 2 pp1241-1242,10.1136/annrheumdis-2016-eular.4076,,,,Missing EZProxy credentials.,unreachable,,na
9738771,"Pazmino SS; Westhovens R; Joly J; Stouten V; De Cock D; Van der Elst K; Verschueren P. Two year cost-effectiveness analysis of the carera trial in early RA: a piggy back study. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp197",10.1136/annrheumdis-2018-eular.7296,,,,Missing EZProxy credentials.,unreachable,,na
9739488,Van Der Elst K; De Cock D; Stouten V; Joly J; Moons P; Verschueren P; Westhovens R. Patients with early rheumatoid arthritis treated with remission induction treat-to-target regimens report important early and lasting health improvement: results from the carera trial. Annals of the rheumatic diseases. (2016) 75  pp690-,10.1136/annrheumdis-2016-eular.5971,,,,Missing EZProxy credentials.,unreachable,,na
9740087,EUCTR2008-007225-39-BE. A 2 year follow up to assess the effectiveness in daily practice of different treatment strategies for early Rheumatoid Arthritis patients. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008-007225-39-BE. (2009)   pp,10.1093/rheumatology/39.4.407,http://academic.oup.com/rheumatology/article-pdf/39/4/407/9532685/390407.pdf,http://academic.oup.com/rheumatology/article-pdf/39/4/407/9532685/390407.pdf,,,pdf,,Article
9740723,Stouten V; De Cock D; Pazmino S; Van Der Elst K; Joly J; Bertrand D; Westhovens R; Verschueren P. Rheumatologists' adherence to the treat-totarget principle in early RA patients within the pragmatic carera trial: room for improvement?. Annals of the rheumatic diseases. (2019) 78  pp342-,10.1136/annrheumdis-2019-eular.7239,,,,Missing EZProxy credentials.,unreachable,,na
9740777,Pazmino S; Boonen A; Stouten V; De Cock D; Bertrand D; Van Der Elst K; Joly J; Westhovens R; Verschueren P; Group CS. Seronegative rheumatoid arthritis: mild no more. Annals of the rheumatic diseases. (2019) 78 Supplement 2 pp317-318,10.1136/annrheumdis-2019-eular.1940,,,,Missing EZProxy credentials.,unreachable,,na
9741315,"Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. Clinical rheumatology. (2020)   pp",10.1007/s10067-020-05008-4,http://link.springer.com/article/10.1007/s10067-020-05008-4/fulltext.html,http://link.springer.com/article/10.1007/s10067-020-05008-4/fulltext.html,,,html,,Article
9742219,"Van Der Elst K; Verschueren P; Stouten V; Pazmino S; De Cock D; Joly J; Moons P; Westhovens R. Rapid and sustained remission contributes to improved psychosocial outcomes after 1 year of treatment in patients with early rheumatoid arthritis: data from the carera trial. Annals of the rheumatic diseases. (2018) Conference: Annual European Congress of Rheumatology, EULAR 2018. Netherlands. 77 Supplement 2 pp557-558",10.1136/annrheumdis-2018-eular.6310,,,,Missing EZProxy credentials.,unreachable,,na
9742393,"Lucio SP; Boonen A; Westhovens R; Stouten V; Joly J; De Cock D; Van Der Elst K; Verschueren P. Two-year cost-utilityand cost-effectiveness analysis of different cobra like intensive remission induction strategies for early rheumatoid arthritis: a piggy back studyon the pragmatic randomized controlled careratrial. Journal of clinical rheumatology. (2019) Conference: 21st Pan American Rheumatology Congress, PANLAR 2019. Ecuador. 25 3 Supplement ppS49",10.1136/annrheumdis-2019-216874,,,,Missing EZProxy credentials.,unreachable,,na
9742465,"Stouten V; Michiels S; Westhovens R; De Cock D; Belba A; Pazmino S; Van der Elst K; Joly J; Verschueren P. Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT. Clinical rheumatology. (2020)   pp",10.1007/s10067-020-05008-4,http://link.springer.com/article/10.1007/s10067-020-05008-4/fulltext.html,http://link.springer.com/article/10.1007/s10067-020-05008-4/fulltext.html,,,html,,Article
9742912,Lucio SP; Boonen A; Westhovens R; Stouten V; Joly J; De Cock D; Van Der Elst K; Verschueren P. Two-year cost-utilityand cost-effectiveness analysis of different cobra like intensive remission induction strategies for early rheumatoid arthritis: a piggy back studyon the pragmatic randomized controlled careratrial. Journal of clinical rheumatology. (2019) 25 3 ppS49-,10.1136/annrheumdis-2019-216874,,,,Missing EZProxy credentials.,unreachable,,na
11084051,"De Cock D; Nooyens A; Pazmino S; Bertrand D; Stouten V; Joly J; Westhovens R; Verschueren P. Treating early and intensively is associated with lower fatigue levels on the long term, even in patients with early rheumatoid arthritis considered to have a favourable risk profile. Annals of the rheumatic diseases. (2020) 79 SUPPL 1 pp583-584",10.1136/annrheumdis-2020-eular.3160,,,,Missing EZProxy credentials.,unreachable,,na
11084739,Doumen M; De Cock D; Pazmino S; Bertrand D; Joly J; Westhovens R; Verschueren P. Psychosocial burden predicts sustained remission in early rheumatoid arthritis: unraveling the complex interplay of wellbeing and disease activity. . (2021)   pp,10.1002/acr.24847,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.24847,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.24847,,,html,,Article
11085370,Pazmino Sofia; Boonen Annelies; De Cock Diederik; Stouten Veerle; Joly Johan; Bertrand Delphine; Westhovens Rene; Verschueren Patrick. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. RMD open. (2021) 7 2 pp,10.1136/rmdopen-2021-001615,,https://rmdopen.bmj.com/rmdopen/7/2/e001615.full.pdf,,,pdf,,Page Not Found
11086492,Pazmino S; Boonen A; Stouten V; De Cock D; Bertrand D; Van Der Elst K; Joly J; Wethovens R; Verschueren P. Seronegative rheumatoidarthritis: mild nomore. Journal of clinical rheumatology. (2020) 20 3 SUPPL 1 ppS135,10.1136/annrheumdis-2019-eular.1940,,,,Missing EZProxy credentials.,unreachable,,na
11088012,"Stouten Veerle; Westhovens Rene; De Cock Diederik; Van der Elst Kristien; Pazmino Sofia; Bertrand Delphine; Joly Johan; Verschueren Patrick. Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial. Rheumatology (Oxford, England). (2021) 60 8 pp3699-3708",10.1093/rheumatology/keaa841,http://academic.oup.com/rheumatology/article-pdf/60/8/3699/39543579/keaa841.pdf,http://academic.oup.com/rheumatology/article-pdf/60/8/3699/39543579/keaa841.pdf,,,pdf,,PDF
9740525,EUCTR2017-004054-41-BE. COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-004054-41-BE. (2018)   pp,10.1186/isrctn75505683,,,,Missing EZProxy credentials.,unreachable,,na
9258631,"Schiff MH; von Kempis J; Goldblum R; Tesser JR; Mueller RB. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Annals of the rheumatic diseases. (2014) 73 12 pp2174-2177",10.1136/annrheumdis-2014-205325,,,,Missing EZProxy credentials.,unreachable,,na
9261158,"Emery P; Smolen JS; Samborski W; Berenbaum F; Davies O; Ambrugeat J; Bennett B; Burkhardt H. Efficacy and safety of certolizumab pegol after incomplete response to dmards in rheumatoid arthritis patients with low moderate disease activity: Results from certain, a phase IIIB study. Rheumatology (United Kingdom). (2012) 51  ppiii134",10.1136/annrheumdis-2012-eular.2607,,,,Missing EZProxy credentials.,unreachable,,na
9737864,"EUCTR2007-000830-38-AT. A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of   certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis who participated in the study C87076. http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2007-000830-38-AT. (2008)   pp",10.1186/isrctn27093749,,,,Missing EZProxy credentials.,unreachable,,na
